drugset
Drugs / HMPL-453
last change Jan 2026 re-read 2 minutes ago

HMPL-453

targets FGFR1, FGFR2, FGFR3 via inhibition

Developed for
cancer · intrahepatic cholangiocarcinoma · malignant mesothelioma · neoplasm
Investigated by
Hutchison Medipharma Limited · Hutchmed

Trials 8 · a red edge is where a trial was stopped

today NCT07697157 · Ph 1 NCT07644442 · Ph 1 NCT05930119 · Ph 1 NCT05173142 · Ph 1/2 NCT04353375 · Ph 2/3 NCT04290325 · Ph 2 NCT03160833 · Ph 1/2 NCT02966171 · Ph 1
201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT07697157 Mar → Dec 2025 — Hutchmed Completed No outcome recorded
Phase 1 NCT07644442 Feb → Mar 2025 — Hutchmed Completed No outcome recorded
Phase 1 NCT05930119 Mar → Aug 2023 intrahepatic cholangiocarcinoma Hutchmed Completed No outcome recorded
Phase 1 NCT02966171 Jan 2017 → Aug 2018 cancer Hutchison Medipharma Limited Terminated No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05173142 Jan 2022 → Jul 2025 neoplasm Hutchison Medipharma Limited Completed No outcome recorded
Phase 1/2 NCT03160833 May 2017 → Dec 2019 cancer Hutchison Medipharma Limited Unknown No outcome recorded
Phase 21 trial
Phase 2 NCT04290325 Dec 2019 → Nov 2022 malignant mesothelioma Hutchison Medipharma Limited Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04353375 Sep 2020 → Jun 2028 expected intrahepatic cholangiocarcinoma Hutchmed Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as HMPL-453 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04290325 ↗
7

NCT04353375 ↗

NCT02966171 ↗

NCT05173142 ↗

NCT03160833 ↗

NCT07644442 ↗

NCT05930119 ↗

NCT07697157 ↗
Action Inhibit “Fibroblast growth factor receptor 1 inhibitor” CHEMBL4650297 ↗
3

“Fibroblast growth factor receptor 2 inhibitor” CHEMBL4650297 ↗

“Fibroblast growth factor receptor 3 inhibitor” CHEMBL4650297 ↗

“FGFR Inhibitor” NCT07644442 ↗
Route Oral “oral administration” NCT02966171 ↗
Target FGFR1 “Fibroblast growth factor receptor 1 inhibitor” CHEMBL4650297 ↗
Target FGFR2 “Fibroblast growth factor receptor 2 inhibitor” CHEMBL4650297 ↗
Target FGFR3 “Fibroblast growth factor receptor 3 inhibitor” CHEMBL4650297 ↗